Engineered T-Cells take on HIV in early trial
NCT ID NCT03617198
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage study tests a new approach to HIV treatment. Researchers take a person's own T-cells, modify them to better recognize and attack HIV, and infuse them back. The main goal is to check safety in 12 stable HIV patients, while also seeing if the modified cells can help control the virus.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- genetically modified T-cells (CD4 CAR+CCR5 ZFN T-cells)
- What this could lead to
- If successful, this could point toward a way to control HIV without daily medication, by training the immune system to attack infected cells.
- What could go wrong
- This is a very early, small safety trial with only 12 people. The modified cells may not work as hoped, and there are risks of side effects from the cell infusion.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Peer support may lift the cloud of loneliness for older gay men with HIV
- Can peer mentors help gay men with HIV stay in care?
- HIV and hidden health risks: a major study probes the link
- Faith-Based therapy aims to heal trauma in young women
- Bringing HIV care to the community: a new test in zambia
- Could intense workouts reverse cognitive decline in older HIV patients?